03320 PE Ratio & Valuation,Is 03320 Overvalued — Intellectia
03320 Relative Valuation
03320's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 03320 is overvalued; if below, it's undervalued.
Historical Valuation
CHINARES PHARMA(03320) is now in theFairzone, suggesting that its currentforward PEratio of6.89is consideredFairlycompared with the five-year average of7.40.The fair price ofCHINARES PHARMA(03320)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.53
Fair
6.89
PE
1Y
3Y
5Y
Trailing
Forward
8.34
EV/EBITDA
CHINARES PHARMA. (03320) has a current EV/EBITDA of 8.34. The 5-year average EV/EBITDA is 7.58. The thresholds are as follows: Strongly Undervalued below 6.68, Undervalued between 6.68 and 7.13, Fairly Valued between 8.03 and 7.13, Overvalued between 8.03 and 8.49, and Strongly Overvalued above 8.49. The current Forward EV/EBITDA of 8.34 falls within the Overvalued range.
9.96
EV/EBIT
CHINARES PHARMA. (03320) has a current EV/EBIT of 9.96. The 5-year average EV/EBIT is 8.93. The thresholds are as follows: Strongly Undervalued below 7.81, Undervalued between 7.81 and 8.37, Fairly Valued between 9.49 and 8.37, Overvalued between 9.49 and 10.04, and Strongly Overvalued above 10.04. The current Forward EV/EBIT of 9.96 falls within the Overvalued range.
0.09
PS
CHINARES PHARMA. (03320) has a current PS of 0.09. The 5-year average PS is 0.12. The thresholds are as follows: Strongly Undervalued below 0.08, Undervalued between 0.08 and 0.10, Fairly Valued between 0.13 and 0.10, Overvalued between 0.13 and 0.15, and Strongly Overvalued above 0.15. The current Forward PS of 0.09 falls within the Undervalued range.
1.74
P/OCF
CHINARES PHARMA. (03320) has a current P/OCF of 1.74. The 5-year average P/OCF is 4.20. The thresholds are as follows: Strongly Undervalued below -1.50, Undervalued between -1.50 and 1.35, Fairly Valued between 7.05 and 1.35, Overvalued between 7.05 and 9.90, and Strongly Overvalued above 9.90. The current Forward P/OCF of 1.74 falls within the Historic Trend Line -Fairly Valued range.
-22.12
P/FCF
CHINARES PHARMA. (03320) has a current P/FCF of -22.12. The 5-year average P/FCF is 5.67. The thresholds are as follows: Strongly Undervalued below -75.23, Undervalued between -75.23 and -34.78, Fairly Valued between 46.12 and -34.78, Overvalued between 46.12 and 86.57, and Strongly Overvalued above 86.57. The current Forward P/FCF of -22.12 falls within the Historic Trend Line -Fairly Valued range.
CHINARES PHARMA (03320) has a current Price-to-Book (P/B) ratio of 0.52. Compared to its 3-year average P/B ratio of 0.68 , the current P/B ratio is approximately -23.76% higher. Relative to its 5-year average P/B ratio of 0.64, the current P/B ratio is about -19.59% higher. CHINARES PHARMA (03320) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 40.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 34.88% , the current FCF yield is about -100.00% lower.
0.52
P/B
Median3y
0.68
Median5y
0.64
66.82
FCF Yield
Median3y
40.03
Median5y
34.88
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 03320 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 03320 in the past 1 year is driven by Unknown.
Is CHINARES PHARMA (03320) currently overvalued or undervalued?
CHINARES PHARMA(03320)is now in theFairzone, suggesting that its currentforward PEratio of 6.89is consideredFairlycompared with the five-year average of7.40.The fair price of CHINARES PHARMA(03320)is betweentoaccording to relative valuation methord.
What is CHINARES PHARMA (03320) fair value?
03320's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CHINARES PHARMA (03320) is between to according to relative valuation methord.
How does 03320's valuation metrics compare to the industry average?
The average P/S ratio for 03320's competitors is , providing a benchmark for relative valuation. CHINARES PHARMA Corp (03320) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for CHINARES PHARMA (03320) as of Dec 17 2025?
As of Dec 17 2025, CHINARES PHARMA (03320) has a P/B ratio of 0.52. This indicates that the market values 03320 at 0.52 times its book value.
What is the current FCF Yield for CHINARES PHARMA (03320) as of Dec 17 2025?
As of Dec 17 2025, CHINARES PHARMA (03320) has a FCF Yield of 0.00%. This means that for every dollar of CHINARES PHARMA’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for CHINARES PHARMA (03320) as of Dec 17 2025?
As of Dec 17 2025, CHINARES PHARMA (03320) has a Forward P/E ratio of 6.89. This means the market is willing to pay $6.89 for every dollar of CHINARES PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CHINARES PHARMA (03320) as of Dec 17 2025?
As of Dec 17 2025, CHINARES PHARMA (03320) has a Forward P/S ratio of 0.00. This means the market is valuing 03320 at $0.00 for every dollar of expected revenue over the next 12 months.
